Sectors News Results

  • Compression Garments Market Size to Reach Revenues around USD 4 Billion by 2025 - Arizton

    CHICAGO, Oct. 28, 2020 In-depth analysis and data-driven insights on the impact of COVID-19 included in this global compression garments market report. The global compression garments market is expected to grow at a CAGR of approximately 5% during the period 2019−2025. Key Highlights Offered in the Report:  . Key Offerings: Get your sample today!

  • GSK expects full-year earnings to be at lower end of its forecast

    Britain's GSK said on Wednesday it expects full-year adjusted earnings to be at the lower end of its forecast as the COVID-19 pandemic disrupts vaccination rates, especially for its blockbuster shingles vaccine. The world's largest vaccine maker now expects 2020 profit to be at the lower end of its forecast of a 1%-4% drop, which did not include any potential impact from the coronavirus crisis.

  • Eli Lilly Earnings, Halted Covid-19 Drug Trial Disappoint Investors -- Update

    Eli Lilly& Co. reported lower-than-expected quarterly earnings due to pricing pressure on top products, while the drugmaker said it would proceed with plans to introduce a new Covid-19 antibody treatment despite a setback in one of several clinical studies of its uses. The Indianapolis-based company said it would continue pursuing U.S. authorization for an antibody drug to treat Covid-19 patients in the early course of illness and with a mild to moderate version of the...

  • Eli Lilly Earnings, Halted Covid-19 Drug Trial Disappoint Investors

    Eli Lilly& Co. reported lower-than-expected quarterly earnings due to pricing pressure on top products, while the drugmaker said it would proceed with plans to introduce a new Covid-19 antibody treatment despite a setback in one of several clinical studies of its uses. The Indianapolis-based company said it would continue pursuing U.S. authorization for an antibody drug to treat Covid-19 patients in the early course of illness and with a mild to moderate version of the...

  • Ben Franklin Tech Partners to Invest $407K in PA Companies

    The Ben Franklin Technology Partners of Northeastern Pennsylvania’s Board of Directors has approved the investment of $407,130 in support of regional economic development.

  • Pandemic Dents Third-Quarter Sales for Pfizer -- Update

    The Covid-19 pandemic weighed down sales for some Pfizer Inc. (PFE) drugs in the latest quarter as the company's candidate vaccine for the virus that has caused the public-health crisis continues in a large late-stage trial. The New York City-based company recorded sales of $12.13 billion, compared with $12.68 billion in the same three- month period last year. Analysts surveyed by FactSet had forecast $12.31 billion of sales.

  • BRIEF-Pfizer Inc Reports Adjusted Earning Of $0.72 Per Share

    Pfizer Inc (PFE): * THIRD-QUARTER 2020 REVENUES OF $12.1 BILLION. * QUARTERLY REPORTED DILUTED EPS OF $0.39, ADJUSTED DILUTED EPS OF $0.72. * PFIZER - REAFFIRMED ALL 2020 FINANCIAL GUIDANCE COMPONENTS FOR NEW PFIZER AND UPJOHN AND PROJECTED REVENUE CAGR OF AT LEAST 6% FOR NEW PFIZER THROUGH 2025. * Q3 EARNINGS PER SHARE VIEW $0.71, REVENUE VIEW $12.32 BILLION -- REFINITIV IBES DATA.

  • Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

    Bayer agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany's Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday.

  • Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy

    BERLIN---- Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc., a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas.

  • Gilead Sciences Completes Acquisition of Immunomedics, Inc.

    Gilead Sciences, Inc. (GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics (IMMU) team to the Gilead family.

Search News

Filter Results

Publication Date
Topic
Provider

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.